SOPHiA GENETICS SA

What they do

The company operates a Software-as-a-Service platform, SOPHiA DDM, which analyzes complex genomic data for healthcare providers, primarily in oncology and other inherited conditions. It generates revenue through platform subscriptions, workflow equipment sales, and related services. The company also sells workflow equipment (e.g., consumables and instruments) that integrates with its data platform, and offers services such as setup, training, and support.

Revenue drivers

• SOPHiA DDM Platform — Cloud-based data analysis and interpretation platform; primary recurring revenue source, subscription-based.
• Workflow Equipment and Services — Sale of instruments, consumables, and related service contracts alongside the platform; complements platform adoption.
• Geographic Expansion: EMEA and North America — Revenue from Europe, Middle East, and Africa, and North America are the largest regional contributors; growth from these regions drives overall revenue.

Recent performance

For fiscal year 2025, total revenue was approximately $99.3 million, up from $89.5 million in 2024, representing 11% growth. Adjusted EBITDA improved to a loss of $24.3 million from a loss of $26.4 million in 2024. The company reported a net loss of $80.4 million in 2025 versus $77.9 million in 2024. Gross margin on platform revenue expanded, and the company ended 2025 with $60.3 million in cash and cash equivalents.

Strategy

Management focuses on expanding the installed base of the SOPHiA DDM platform, particularly in oncology, by deepening relationships with existing customers and entering new geographies. The company is investing in artificial intelligence and machine learning capabilities to enhance data interpretation. It also aims to drive higher-margin platform revenue growth while improving operational efficiency to reduce cash burn.

Risks

• Dependence on a Limited Customer Base — One customer accounted for 12% of revenue in 2025, and the loss or reduction of this customer could materially affect results.
• Operating Losses and Cash Needs — The company has a history of net losses and may need additional financing to fund operations and growth.
• Competitive Market — Faces competition from in-house analytics at large health systems and other genomic data analysis vendors, which could pressure pricing or adoption.
• Regulatory and Data Privacy — Serves healthcare providers subject to laws like HIPAA and GDPR; compliance with evolving data protection regulations could increase costs or limit expansion.

Outlook

Management expects continued revenue growth as the company scales the SOPHiA DDM platform, with a focus on achieving adjusted EBITDA break-even in the coming years. They intend to maintain investment in product development and international expansion, while closely managing operating expenses. The company does not provide specific revenue guidance.